Robert Lowsky

Clinical Trials

• Recruiting TLI & ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPD
• Recruiting Allogeneic Transplantation Using TL1 & ATG for Older Patients With Hematologic Malignancies
• Recruiting Double Cord Versus Haploidentical (Blood and Marrow Transplant Clinical Trials Network #1101)
• Recruiting Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies
• Recruiting A Database Study for Hematopoietic Stem Cell Transplantation and Marrow Injuries
• Recruiting Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study
• Recruiting Post T-plant Infusion of Allogeneic Cytokine Induced Killer Cells as Consolidate Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders
• Recruiting Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801)
• Recruiting Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant
• Recruiting Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702)
• Recruiting Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma
• Recruiting Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia
• Recruiting Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML
• Recruiting Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma
• Not Recruiting Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD)
• Not Recruiting Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT
• Not Recruiting Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
• Recruiting Combined Blood Stem Cell and Human Leukocyte Antigen (HLA) Haplotype Match Living Donor Kidney Transplantation
• Not Recruiting Comparing Peripheral Blood Stem Cell Transplantation Versus Bone Marrow Transplantation in Individuals With Hematologic Cancers
• Not Recruiting Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)
• Not Recruiting Vaccine Therapy for Multiple Myeloma Utilizing Idiotype-Pulsed Allogeneic Dendritic Cells
• Not Recruiting Phase II Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD
• Not Recruiting Sirolimus as Treatment of Steroid-Refractory or Steroid-Dependent Chronic Graft-Versus-Host Disease
• Not Recruiting Mixed Chimera Allogeneic Transplantation From Matched Unrelated Donors For The Treatment Of Multiple Myeloma
• Not Recruiting High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplant for Non-Hodgkin's Lymphoma
• Not Recruiting Sirolimus and Mycophenolate Mofetil as Graft Versus Host Disease Prophylaxis in Myeloablative Matched Related Donor Hematopoietic Cell Transplant
• Not Recruiting Allogeneic Transplantation From Related Haploidentical Donors in Older Patients With Indolent Hematologic Malignancies
• Not Recruiting Allogeneic Transplantation for Patients With Acute Leukemia or Chronic Myelogenous Leukemia (CML)
• Not Recruiting Allo BMT in Advanced Leukemia or High Grade Lymphoma
• Not Recruiting A Phase II Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft Versus Host Disease
• Not Recruiting Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease
• Not Recruiting Autologous Stem Cell Rescue for Primary Amyloidosis
• Not Recruiting Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients
• Not Recruiting Ph II of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG
• Not Recruiting A Pilot Study of Imatinib Mesylate in Steroid Refractory Chronic Graft Versus Host Disease
• Not Recruiting High -Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma
• Not Recruiting A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Palifermin (rHuKGF) in the Reduction of Acute Graft Versus Host Disease in Subjects With Hematologic Malignancies Undergoing Allogeneic Marrow/PBPC Transplantation
• Not Recruiting Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies
• Not Recruiting A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)
• Not Recruiting Mixed Chimera Allo Transplantation in Multiple Myeloma
• Not Recruiting Haploid Allogeneic Transplant Using the CliniMACS System
• Not Recruiting Phase II Poor Risk Diffuse Large B-cell Lymphoma (DLBCL) of Total Lymphoid Irradiation (TLI) and Antithymocyte Globulin (ATG) Followed by Matched Allogeneic Hematopoietic Transplantation as Consolidation to Autologous Hematopoietic Cell Transplantation (AHCT)
• Not Recruiting 90Y-IBRITUMOMAB Tiuxetan and AHCI With HD Chemotherapy and Autologous Transplantation for Relapsed or Resistant NHL
• Recruiting Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder
• Recruiting Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT)
• Recruiting Phase I/II MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell
• Recruiting Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)